2022-02-07T12:50:17-06:00 2021-06-30 135565207 KPMG LLP 345 PARK AVENUE NEW YORK NY 101540102 990 2020-07-01 135644916 THE LEUKEMIA & LYMPHOMA SOCIETYINC INC LEUK 9149495213 7111 WEST 151 STREET PMB 317 OVERLAND PARK KS 66223 GORDON MILLER JR EVP CHIEF FIN OFFICE 3125687727 2022-02-02 true GORDON MILLER XXX-XX-XXXX DAVID M HIGHFILL P01517891 2127589700 2022-02-02 2020 2022-09-23 18:48:47Z LOUIS J DEGENNARO 3 INTERNATIONAL DRIVE SUITE 200 RYE BROOK NY 10573 538944536 false X WWW.LLS.ORG X 1949 NY OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES. 19 19 1300 3000000 0 427419530 441317494 15997252 12281240 33847009 12298324 18957518 11766658 496221309 477663716 169606729 152554274 0 126383366 113748897 4373282 9126288 54854964 93633073 84418720 393996450 359848179 102224859 117815537 581677610 743613782 215555172 229841284 366122438 513772498 X OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES. false false 59637481 33928340 12281240 A) RESEARCH PROGRAMS: AT LLS, WE ARE PUSHING BOUNDARIES TOWARD POWERFUL NEW THERAPIES. WE PROPEL GROUNDBREAKING CANCER TREATMENTS THROUGH ALL PHASES OF THE DRUG APPROVAL PROCESS AND ARE PROUD THAT OUR SUPPORT HAS BEEN KEY TO ADVANCING 75% OF THE ALMOST 100 BLOOD CANCER TREATMENT APPROVALS OVER THE LAST FIVE YEARS. AS WE CONTINUED TO SUPPORT THE SEARCH FOR LIFESAVING AND LESS TOXIC TREATMENTS IN 2021, WE INVESTED IN EXCITING RESEARCH FRONTIERS, INCLUDING PRECISION MEDICINE, IMMUNOTHERAPY, AND LINKS BETWEEN MUTATIONS AND BLOOD CANCER-ADVANCEMENTS THAT ARE CHANGING THE PARADIGM OF CANCER TREATMENT. IN THE PROCESS, WE PROPELLED SEVERAL NOVEL SCIENCE INITIATIVES TO NEW HEIGHTS-MANY OF WHICH HARDLY SEEMED POSSIBLE JUST A SHORT TIME AGO. WITH ADVISORY INPUT FROM RECOGNIZED BIOMEDICAL RESEARCH EXPERTS, LLS FUNDS EXEMPLARY PROJECTS ACROSS THE ENTIRE RESEARCH CONTINUUM RELEVANT TO IMPROVE OUTCOMES FOR BLOOD CANCER PATIENTS, FROM BASIC LABORATORY SCIENCE THROUGH CLINICAL TRIALS, AND FROM INVESTIGATOR-INITIATED RESEARCH TO PRIVATE-SECTOR DRUG DEVELOPMENT ALLIANCES. LLS IS DELIBERATE AND PURPOSEFUL IN FINDING AND SUPPORTING RESEARCH THAT IS MOST LIKELY TO HELP PATIENTS AS SOON AS POSSIBLE. TO DATE, LLS HAS INVESTED OVER 1.5 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. IN FISCAL YEAR 2021, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 6 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 33.9 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. IMPACT RESEARCH GRANTS TO ADDRESS UNEQUAL REPRESENTATION OF UNDERSERVED POPULATIONS IN CLINICAL TRIALS, IN MAY WE INTRODUCED IMPACT (INFLUENTIAL MEDICINE PROVIDING ACCESS TO CLINICAL TRIALS) RESEARCH GRANTS. AN INITIAL FIVE-YEAR INVESTMENT OF 3.75 MILLION WAS ALLOCATED TO MAYO CLINIC, VANDERBILT UNIVERSITY MEDICAL CENTER, AND WEILL CORNELL MEDICINE IN NEW YORK CITY. THE IMPACT GRANTS WILL HELP THESE MAJOR CANCER CENTERS EXPAND CLINICAL TRIAL ACCESS TO LOCAL COMMUNITY-BASED HOSPITALS AND CLINICS WITH SUBSTANTIAL UNDERSERVED POPULATIONS. THE GOAL IS TO INCREASE TRIAL ENROLLMENT AMONG TRADITIONALLY UNDERSERVED POPULATIONS, INCLUDING RACIAL AND ETHNIC MINORITIES, RURAL RESIDENTS, AND INDIVIDUALS WITH LOW INCOME, TO AT LEAST 20%, THEREBY EXPANDING ACCESS TO STATE-OF-THE-ART THERAPIES TO A BROADER SWATH OF NEWLY DIAGNOSED BLOOD CANCER PATIENTS. THERAPY ACCELERATION PROGRAM (TAP) SINCE 2007, OUR INNOVATIVE VENTURE PHILANTHROPY INITIATIVE, THE LLS THERAPY ACCELERATION PROGRAM (TAP), HAS PARTNERED WITH BIOTECHNOLOGY COMPANIES AND ACADEMIC RESEARCHERS TO EXTEND THE THERAPEUTIC LANDSCAPE IN LEUKEMIA, LYMPHOMA, AND MULTIPLE MYELOMA. IN 2021, WE MADE SIX NEW INVESTMENTS IN COMPANIES DEVELOPING NEW IMMUNOTHERAPIES INCLUDING "OFF THE SHELF" CAR T-CELL THERAPY, "IN VIVO" THERAPY THAT GENERATES CANCER-FIGHTING CAR CELLS INSIDE THE BODY, TWO FIRST-IN-CLASS ANTIBODIES TARGETING NOVEL CHECKPOINTS, TO RELEASE THE BRAKES AND ACTIVATE IMMUNE CELLS SO THEY CAN FIGHT CANCER, AND CAR- MACROPHAGE (CAR-M) THERAPY TO TREAT CANCERS WHERE CHECKPOINT INHIBITORS TEND TO BE LESS EFFECTIVE. NATIONAL PATIENT REGISTRY COVID INFORMATION THE ONGOING COVID-19 PANDEMIC ENGENDERED A HOST OF FEARS AND QUESTIONS FOR THE BLOOD CANCER COMMUNITY. WHEN PATIENT CONCERNS AROSE ABOUT WHETHER THE NEW VACCINES WOULD PROTECT THEM, LLS STEPPED IN TO FIND ANSWERS. IN FEBRUARY 2021, LLS ACTIVATED THE LLS NATIONAL PATIENT REGISTRY, A PROJECT SUPPORTED BY ETHEL AND BERNARD GARIL IN MEMORY OF THEIR SON, MICHAEL, WHO SUCCUMBED TO ACUTE LYMPHOBLASTIC LEUKEMIA. MORE THAN 10,000 BLOOD CANCER PATIENTS ANSWERED THE CALL TO JOIN THE REGISTRY AS "CITIZEN SCIENTISTS." THIS ALLOWED US TO GENERATE THE LARGEST DATA SET REPORTED TO DATE ON VACCINE SAFETY AND EFFICACY(INCLUDING BOOSTERS) ACROSS ALL MAJOR BLOOD CANCER AND TREATMENT TYPES. THIS INFORMATION HAS HELPED PATIENTS, HEALTHCARE PROVIDERS, AND PUBLIC HEALTH OFFICIALS MAKE MORE INFORMED CHOICES ABOUT COVID-19 PREVENTION. CLINICAL TRIALS BEAT AML MASTER TRIAL BEGINNING NOVEMBER 2016, LLS LAUNCHED THE BEAT AML MASTER TRIAL, A COLLABORATIVE CLINICAL TRIAL TESTING SEVERAL NOVEL TARGETED THERAPIES FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) DESIGNED TO FACILITATE FDA APPROVAL OF NEW DRUGS AND CHANGE THE TREATMENT PARADIGM FOR PATIENTS DIAGNOSED WITH AML BY DEVELOPING MORE INDIVIDUALIZED, EFFECTIVE TREATMENT APPROACHES. THE MASTER TRIAL INVOLVES COLLABORATIONS WITH MULTIPLE MEDICAL INSTITUTIONS, DRUG COMPANIES, A GENOMIC PROVIDER, A CLINICAL RESEARCH ORGANIZATION, AND THE FDA, ALL OF WHOM HAVE COMMITTED TO WORKING COLLABORATIVELY. IN FISCAL YEAR 2021, UP TO 35 PATIENTS PARTICIPATED IN CLINICAL TRIALS UNDER THE BEAT AML MASTER TRIAL. 164688249 118625934 B) PATIENT & COMMUNITY SERVICES: AN ESTIMATED 1.3 MILLION PEOPLE ACROSS THE UNITED STATES (US) ARE CURRENTLY LIVING WITH OR ARE IN REMISSION FROM LEUKEMIA, LYMPHOMA AND MYELOMA. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) OFFERS AN ARRAY OF FREE, COMPREHENSIVE RESOURCES TO BLOOD CANCER PATIENTS, CAREGIVERS, FAMILIES AND FRIENDS OF PATIENTS, ADVOCATES, HEALTHCARE PROFESSIONALS AND THE PUBLIC. LLS IS COMMITTED TO PROVIDING THE MOST ACCURATE AND UP-TO-DATE BLOOD CANCER INFORMATION. PROFESSIONAL VOLUNTEER CLINICAL ADVISORS WORK WITH LLS STAFF TO REVIEW ALL OF THE INFORMATION LLS PROVIDES THROUGH HEALTHCARE PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE LLS WEBSITE. SUPPORT SERVICES ARE PROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE-TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. FINANCIAL ASSISTANCE OUR FINANCIAL ASSISTANCE PROGRAMS AIM TO LESSEN THE ECONOMIC TOLL ON PATIENTS AND FAMILIES TO HELP PATIENTS AFFORD LIFE-SAVING TREATMENTS. TO COUNTER CONTINUALLY RISING DRUG PRICES AND THE ONGOING FINANCIAL IMPACT OF COVID-19, WE PROVIDED MORE THAN 45,000 PATIENTS WITH OVER 241M IN TOTAL GRANTS, A 70% INCREASE OVER LAST YEAR. THE LION'S SHARE-OVER 234 MILLION- SUPPORTED PATIENTS' INSURANCE PREMIUMS AND TREATMENT-RELATED CO-PAY AND CO-INSURANCE OUT OF POCKET COSTS THROUGH OUR CO-PAY ASSISTANCE PROGRAM. IN KEEPING WITH OUR COMMITMENT TO DIVERSITY, EQUITY, AND INCLUSION, LLS RECOGNIZES THAT NEED EXISTS THROUGHOUT ALL GEOGRAPHIC REGIONS AND WITHIN ALL PATIENT POPULATIONS, INCLUDING THOSE TRADITIONALLY UNDERREPRESENTED. IN 2021, FINANCIAL ASSISTANCE WAS PROVIDED TO PATIENTS WHO RESIDED IN 55% OF ALL U.S. COUNTIES AND 51% OF THE COUNTIES ACROSS THE U.S. WITH THE HIGHEST POVERTY RATES. CO-PAY ASSISTANCE PROGRAM THE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO- PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2021, CO-PAY ASSISTANCE WAS PROVIDED TO OVER 22,000 PATIENTS. SUSAN LANG PRE CAR T-CELL THERAPY TRAVEL ASSISTANCE PROGRAM LLS PROVIDED OVER 200 GRANTS, EACH 2,500, FOR TREATMENT-RELATED TRANSPORTATION AND LODGING COSTS FOR PATIENTS WHO ARE BEING EVALUATED TO RECEIVE CAR T-CELL THERAPY AS EITHER STANDARD TREATMENT OR A CLINICAL TRIAL. SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM LLS AWARDED A 500 GRANT TO OVER 4,750 PATIENTS FOR TREATMENT-RELATED TRANSPORTATION AND LODGING COSTS. URGENT NEED PROGRAM IN PARTNERSHIP WITH MOPPIE'S LOVE AND CHARLIE'S FUND, LLS PROVIDED A 500 GRANT TO NEARLY 9,000 PATIENTS AND FAMILIES IN ACUTE FINANCIAL NEED FOR NON-MEDICAL LIVING EXPENSES-INCLUDING RENT, UTILITIES AND FOOD. PATIENT AID PROGRAM LLS PROVIDED A ONE-TIME STIPEND OF 100 TO OVER 3,700 PATIENTS TO HELP OFFSET NON-MEDICAL EXPENSES. SCHOLARSHIP FOR BLOOD CANCER SURVIVORS NEW IN 2021 WAS THE INTRODUCTION OF LLS'S SCHOLARSHIP FOR BLOOD CANCER SURVIVORS PROVIDING UP TO 7,500 IN TUITION SUPPORT FOR PATIENTS DIAGNOSED BEFORE AGE 25, ARE U.S. CITIZENS OR PERMANENT RESIDENTS PURSUING VIRTUAL OR IN-PERSON, VOCATIONAL, 2 YEAR OR 4 YEAR POST-SECONDARY EDUCATION. 21415572 C) PUBLIC HEALTH EDUCATION: LLS BELIEVES KNOWLEDGE IS POWER. AS ALWAYS, LLS HAS OFFERED THEIR INFORMATIONAL PROGRAMS IN VIRTUAL FORMATS, CONTINUING TO PROVIDE VITALLY NEEDED EDUCATION AND EMOTIONAL SUPPORT FOR THOSE IMPACTED BY BLOOD CANCER. ONGOING PANDEMIC CONCERNS TRAINED ONCOLOGY INFORMATION SPECIALISTS IN OUR INFORMATION RESOURCE CENTER (IRC) WERE AVAILABLE TO ANSWER PANDEMIC-RELATED AND OTHER QUESTIONS. OVER 26,000 INTERACTIONS BETWEEN THE IRC AND PATIENTS AND CAREGIVERS TOOK PLACE, WITH AVERAGE CALL LENGTHS UP 30% OVER 2020. FACILITATING CLINICAL TRIAL ACCESS THE LLS CLINICAL TRIAL SUPPORT CENTER (CTSC) GREW THROUGHOUT THE YEAR AS WE INCREASED OUR BI-LINGUAL AND PEDIATRIC EXPERTISE AMONG THE CTSC NURSE NAVIGATORS, AND CONTINUED TO EXPAND THE POSSIBILITY OF POSITIVE OUTCOMES FOR PATIENTS BY MATCHING THEM TO SUITABLE CLINICAL TRIALS. OUR NURSE NAVIGATORS ASSISTED 1,019 PATIENTS (UP 31% FROM 2020). OF THE 759 NEW PATIENTS ASSISTED (UP 31% FROM LAST YEAR), 21% ENTERED A TRIAL. WE WERE HONORED THAT A CTSC TEAM-AUTHORED ARTICLE, OVERCOMING BARRIERS TO CLINICAL TRIAL PARTICIPATION: OUTCOMES OF A NATIONAL CLINICAL TRIAL MATCHING AND NAVIGATION SERVICE FOR PATIENTS WITH A BLOOD CANCER, WAS PUBLISHED IN THE "JOURNAL OF CLINICAL ONCOLOGY, ONCOLOGY PRACTICE" IN MAY. OUTREACH TO UNDERSERVED GROUPS WE AUGMENTED EFFORTS TO EXPAND ACCESS TO LLS SERVICES AND RESOURCES BY BOLSTERING RELATIONS WITH COMMUNITY GROUPS AND LEADERS, NOTABLY IN THE AFRICAN AMERICAN AND LATINO COMMUNITIES, AND INCREASED OUR NUMBER OF BILINGUAL VOLUNTEERS. WE ALSO INCREASED ACCESSIBILITY OF OUR EDUCATION PROGRAMS TO RURAL PATIENTS AND FAMILIES VIA OUR VIRTUAL OFFERINGS. MOREOVER, WE EXPANDED PARTNERSHIPS WITH AFFINITY GROUPS INCLUDING: THE COALITION OF 100 BLACK WOMEN, THE MEXICAN CONSULATE'S VENTANILLA DE SALUD PROGRAM,AND PROMOTORES (VISION Y COMPROMISO). THE LLS MYELOMA LINK PROGRAM, LAUNCHED IN 2017, CONTINUED TO GAIN TRACTION. WE IMPROVED UNDERSTANDING OF TREATMENT OPTIONS BY PROVIDING IMPORTANT INFORMATION TO AFRICAN AMERICANS, WHO ARE TWICE AS LIKELY TO BE DIAGNOSED WITH MULTIPLE MYELOMA AS CAUCASIAN AMERICANS. IN 2021, LLS REACHED APPROXIMATELY 10,448 PEOPLE THROUGH MORE THAN 72 MYELOMA LINK EDUCATION AND OUTREACH ACTIVITIES IN 13 CITIES. EDUCATION AND PATIENT CONNECTIONS OUR VIRTUAL EDUCATION PROGRAMS PROVIDED BOTH PATIENTS AND FAMILIES, AS WELL AS HEALTH CARE PROFESSIONALS, ACCESS TO CONTENT INCLUDING BLOOD CANCER CONFERENCES, LOCAL EDUCATION PROGRAMS, NATIONAL WEBINARS, VIDEOS, LECTURES, AND PODCASTS. LLS'S HIGHLY VIEWED WEBSITE CONTINUES TO PROVIDE THE MOST UP TO DATE BLOOD CANCER INFORMATION INCLUDING ACCESS TO BLOGS, BOOKLETS, WORKBOOKS, FACT SHEETS AND MORE. IN ADDITION, NEARLY 1,000 CANCER PATIENTS WERE PROVIDED WITH PERSONALIZED NUTRITION CONSULTATIONS BY LLS'S REGISTERED DIETITIAN. OUR PATIENT & COMMUNITY OUTREACH TEAM CONTINUED TO BRING PATIENTS TOGETHER VIA ONLINE LOCAL SUPPORT GROUPS AND CHATS. THE PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM MATCHED NEARLY 1,800 PATIENTS (UP 5% FROM 2020) WITH TRAINED VOLUNTEERS FACING THE SAME DISEASE, HELPING TO AVERT PANDEMIC-RELATED ISOLATION. IN ADDITION, MEMBERSHIP IN LLS COMMUNITY-OUR ONLINE SOCIAL NETWORK-INCREASED 23% OVER 2020. 9280825 D) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. UPCOMING AND ARCHIVED CE/CME PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/CE. IN FY 2021: -LLS PROVIDED 14 CME/CE-GRANTING VIRTUAL EDUCATIONAL PROGRAMS, WITH 2,345 HEALTHCARE PROFESSIONALS IN ATTENDANCE. --THERE WERE 44,790 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS, 25,541 VIRTUAL LECTURE VIEWS AND 14,107 PODCAST DOWNLOADS. 9280825 255022127 true true false true false false false true false true true false false false false true false true false true true true false true true true false true true true false false false false false false false false true false false false true true true true false false true 267 0 true 1300 true false true CA false false false true true false false false false false false X 19 19 false false false false false false false true true false true true true true true true true true true true false AK AL AR AZ CA CO CT DE DC FL GA HI ID IL IN KS KY LA MA MD ME MI MN MO MS NH NJ NM NE NY OH OK OR PA PR RI SC TN UT VA WA WI WV X X GORDON MILLER JR 9148218935 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 LOUIS J DEGENNARO PHD PRESIDENT & 40.00 1.00 X 950516 0 41258 GWEN NICHOLS MD EVP CHIEF ME 40.00 X 406230 0 27197 TROY DUNMIRE - START 1132020 EVP CHIEF OP 40.00 X 408554 0 20814 VANESSA WHITE SVP CHIEF AD 40.00 X 355467 0 26217 LEE M GREENBERGER SVP CHIEF SC 40.00 X 325543 0 42366 KATHY GRIESENBECK - END 7312020 EVP CHIEF RE 40.00 X 347706 0 17857 COKER POWELL EVP PROD CAM 40.00 X 320245 0 44460 GORDON MILLER JR EVP CHIEF FI 40.00 1.00 X 321228 0 36312 MARGO LUCERO - END 7312020 EVP CORP PAR 40.00 X 336366 0 19808 ROSEMARIE ALOFFREDO - END 3312019 CHIEF FIN OF 40.00 X 177503 0 0 ALESSANDRA TOCCO - START 712020 BOD MEMBER 4.00 X 0 0 0 FREDA WANG - START 712020 BOD MEMBER 4.00 X 0 0 0 RICH BAGGER - START 712020 BOD MEMBER 4.00 X 0 0 0 RICHARD RENDINA - START 712020 BOD MEMBER 4.00 X 0 0 0 MICHELE CAMERON BOD MEMBER 4.00 X 0 0 0 RALPH E LAWSON FHFMA CPA CHAIRMAN 4.00 X X 0 0 0 RUBEN MESA MD FACP AT LARGE 4.00 X X 0 0 0 JOHN GREENE BOD MEMBER 4.00 X 0 0 0 FRANCIE HELLER BOD MEMBER 4.00 X 0 0 0 CASEY CUNNINGHAM MD BOD MEMBER 4.00 X 0 0 0 CHRISTOPHER FLOWERS MD BOD MEMBER 4.00 X 0 0 0 JANICE GABRILOVE MD BOD MEMBER 4.00 X 0 0 0 RENZO CANETTA MD BOD MEMBER 4.00 X 0 0 0 KATHLEEN MERIWETHER SECRETARY/TR 4.00 X X 0 0 0 LYNNE O'BRIEN BOD MEMBER 4.00 X 0 0 0 MARLA PERSKY BOD MEMBER 4.00 X 0 0 0 ROBERT ROSEN BOD MEMBER 4.00 X 0 0 0 JEFF SACHS VICE CHAIR 4.00 X X 0 0 0 BART SICHEL BOD MEMBER 4.00 X 0 0 0 3949358 276289 236 true true false PATIENT ADVOCACY FOUNDATION 421 BUTLER FARM RD HAMPTON VA 23666 PAT ASSIST PROC 7853107 SYNEOS HEALTH LLC 75 REMITTANCE DRIVE SUITE 3160 CHICAGO IL 606753160 CLINICAL TRIAL 5656214 RESOURCE ONE 2900 EAST APACHE STREET TULSA OK 74110 DIRECT MARKETIN 4630228 MERKLE 29432 NETWORK PLACE CHICAGO IL 606731294 MARKETING 2513376 FACEBOOK 1 HACKER WAY MENLO PARK CA 94025 ADVERTISING 2282901 141 X 2694841 160127233 278495420 1784277 441317494 SERVICE REVENUE 810000 12281240 12281240 12281240 4332782 4332782 12544341 12544341 63571033 55605491 7965542 7965542 7965542 4820136 160127233 5673129 -852993 -852993 77510 2200 75310 75310 477663716 12281240 24064982 29137705 29137705 118625934 118625934 4790635 4790635 1994372 697169 1015200 282003 89968243 45167324 21529702 23271217 3091830 1440530 863958 787342 11667753 5462304 3222357 2983092 7026699 3273845 1963488 1789366 2681155 1608693 723912 348550 441164 441164 1462660 1462660 9126288 9126288 653745 485260 79871 88614 22042230 15988647 3029423 3024160 7062645 4121254 609605 2331786 14763355 8657502 1429009 4676844 12131350 914704 9011167 2205479 8495355 4153398 1624264 2717693 23191 487 8017 14687 3476787 345544 2860942 270301 866139 54649 813298 -1808 RESEARCH AND DEVELOPMENT 6877888 6877888 MISCELLANEOUS 3441056 1755995 745711 939350 359848179 255022127 49971088 54854964 X 15929798 10677326 5252472 27772961 17101591 363331593 118564418 24021989 13531687 3815548 3702570 18569968 7821920 9345892 10748048 138900813 552134623 10426610 20423995 4062204 7406850 581677610 743613782 23457200 28917585 179469755 188608360 12628217 12315339 215555172 229841284 X 249719310 328718773 116403128 185053725 366122438 513772498 581677610 743613782 X 117815537 29836577 -2054 X false true X true false X 314912814 419570497 372750094 427419530 441317494 1975970429 314912814 419570497 372750094 427419530 441317494 1975970429 515721732 1460248697 7018822 8235985 11830162 29082073 16877123 73044165 25439044 70000 25509044 2074523638 90794633 0.70390 0.75400 X PART II, LINE 10 OTHER MISC. REVENUE (YR 2015-2017) 188,848 TAP CONTRACTUAL RETURN (YR 2016) 25,320,196 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED true true true 66059 false true 105098 false true 308666 true 110404 true 1261825 1852052 false SCHEDULE C, PART II-B, LINE 1 LLS IS A MEMBER OF A NUMBER OF COALITIONS AND MEMBERSHIPS INCLUDING FRIENDS OF CANCER RESEARCH, ONE VOICE AGAINST CANCER, NATIONAL HEALTH COUNCIL, THE CANCER LEADERSHIP COUNCIL, AMERICAN CHILDHOOD CANCER ORGANIZATION, PUBLIC AFFAIRS COUNCIL, PATIENT QUALITY OF LIFE COALITION, DEFENSE HEALTH RESEARCH CONSORTIUM, AND THE STATE ACCESS TO INNOVATIVE MEDICINES COALITION. LLS PARTNERS WITH LOBBYING FIRMS WHO WORK WITH OUR PUBLIC POLICY STAFF TO CARRY OUT OUR LOBBYING OBJECTIVES. LLS MOBILIZES PATIENT-ADVOCATES AND VOLUNTEERS TO ENGAGE WITH THEIR FEDERAL AND STATE LEGISLATORS THROUGH DIGITAL ADVOCACY - SENDING LETTERS; SHARING THEIR PERSONAL STORIES; SIGNING PETITIONS; AND ENCOURAGING THEIR LEGISLATORS TO SUPPORT LLS' POLICY PRIORITIES. IN CONJUNCTION WITH LLS EMPLOYEES, PATIENT-ADVOCATES ALSO VISIT THEIR LEGISLATORS IN THEIR LOCAL OFFICES, IN WASHINGTON, DC AND IN STATE CAPITOLS TO FURTHER LLS'S POLICY AGENDA. X false 5902791 1650 1726314 -236177 -13118 7381460 6168319 -8812 -246718 -9998 5902791 6192807 292934 -304999 -12423 6168319 5897377 200 546324 -237896 -13198 6192807 6027967 5200 119369 -240000 -15159 5897377 0.38610 0.61390 false false 1141552 703323 438229 17376846 7067027 10309819 51570 51570 10748048 X 483943939 -7965542 4226745 10186837 6448040 477495899 167737 80 167817 477663716 371594986 4226745 8173806 12400551 359194435 653744 653744 359848179 SCHEDULE D, PAGE 2, PART III, LINE 4 THE LLS COLLECTION IS OF PHOTOGRAPHS WHICH ARE USED FOR PUBLIC EXHIBITION AT FUNDRAISING EVENTS HELD TO SUPPORT LLS'S PROGRAMS. SCHEDULE D, PAGE 2, PART V, LINE 4 LLS'S ENDOWMENTS ARE INTENDED TO FUND RESEARCH AS WELL AS SUPPORT LLS'S PUBLIC EDUCATION PROGRAMS. SCHEDULE D, PAGE 3, PART X LLS, LLSRP, AND LLSRF QUALIFY AS CHARITABLE ORGANIZATIONS AS DEFINED BY INTERNAL REVENUE CODE SECTION 501(C)(3) AND, ACCORDINGLY, ARE EXEMPT FROM FEDERAL INCOME TAXES UNDER INTERNAL REVENUE CODE SECTION 501(A). ADDITIONALLY, SINCE THESE ORGANIZATIONS ARE PUBLICLY SUPPORTED, CONTRIBUTIONS QUALIFY FOR THE MAXIMUN CHARITABLE CONTRIBUTION DEDUCTION UNDER THE INTERNAL REVENUE CODE. LLSC IS REGISTERED AS A CHARITABLE ORGANIZATION UNDER THE INCOME TAX ACT (CANADA) AND IS, THEREFORE, NOT SUBJECT TO INCOME TAXES IF CERTAIN DISBURSEMENT REQUIREMENTS ARE MET. LLS AND ITS RELATED ENTITIES RECOGNIZE THE EFFECT OF TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO LLS'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENUE CODE SECTION 511. THERE WERE NOT ENTITIES THAT RECOGNIZED UNRELATED BUSINESS INCOME TAX LIABILITY FOR THE YEARS ENDED JUNE 30, 2021 AND JUNE 30, 2020. SCHEDULE D, PAGE 4, PART XI, LINE 2D LLS CANADA REVENUE 10,186,837 SCHEDULE D, PAGE 4, PART XI, LINE 4B MISC ROUNDING 80 SCHEDULE D, PAGE 4, PART XII, LINE 2D LLS CANADA EXPENSES 8,173,806 true NORTH AMERICA 4 RESEARCH FUNDING RESEARCH GRANTS 357600 EUROPE 8 RESEARCH FUNDING RESEARCH GRANTS 9662921 CENTRAL AMERICA & CARIBBEAN 4 INVESTMENTS INVESTMENTS 9986931 MIDDLE EAST & NORTH AFRICA 1 RESEARCH FUNDING RESEARCH GRANTS 120000 EAST ASIA & THE PACIFIC 6 RESEARCH FUNDING RESEARCH GRANTS 1764767 23 23 21892219 21892219 EUROPE RESEARCH GRANT 200000 WIRE ACCRUAL EUROPE RESEARCH GRANT 200000 WIRE ACCRUAL EAST ASIA AND PACIFIC RESEARCH GRANT 16750 WIRE ACCRUAL EUROPE RESEARCH GRANT 229969 WIRE ACCRUAL NORTH AMERICA RESEARCH GRANT 15000 WIRE ACCRUAL EUROPE RESEARCH GRANT 146247 WIRE ACCRUAL NORTH AMERICA RESEARCH GRANT 190000 WIRE ACCRUAL NORTH AMERICA RESEARCH GRANT 15000 WIRE ACCRUAL EAST ASIA AND PACIFIC RESEARCH GRANT 41664 WIRE ACCRUAL EAST ASIA AND PACIFIC RESEARCH GRANT 202176 WIRE ACCRUAL EAST ASIA AND PACIFIC RESEARCH GRANT 300000 WIRE ACCRUAL NORTH AMERICA RESEARCH GRANT 326100 WIRE ACCRUAL EUROPE RESEARCH GRANT 14275 WIRE ACCRUAL EAST ASIA AND PACIFIC RESEARCH GRANT 1200000 WIRE ACCRUAL MIDDLE EAST RESEARCH GRANT 120000 WIRE ACCRUAL EUROPE RESEARCH GRANT 67795 WIRE ACCRUAL EUROPE THERAPY ACCELERATION 1499982 WIRE FMV 17 true false true true false false SCHEDULE F, PAGE 1, PART I, LINE 2 FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. THE ACCOUNTING METHOD UTILIZED FOR GRANTS REPORTED ON PART II IS THE ACCRUAL METHOD AS CONSISTENT WITH BOOKS AND RECORDS. SCHEDULE F, PAGE 1, PART I, LINE 3 NORTH AMERICA 357,600 0 EUROPE 9,662,921 0 CENTRAL AMERICA & CARIBBEAN 0 9,986,931 MIDDLE EAST & NORTH AFRICA 120,000 0 EAST ASIA & THE PACIFIC 1,764,767 0 X X X X X X true RESOURCE ONE 2900 EAST APACHE STREET TULSO OK 74110 DIRECT MAI false 4630228 -4630228 THOMPSON HABIB & DENISON 80 HAYDEN AVENUE SUITE 300 LEXINGTON MA 02421 DIRECT MAI false 687311 -687311 MAIL AMERICA COMMUNICATIONS INC PO BOX 870 FORREST VA 245510870 DIRECT MAI false 190269 -190269 COINSTAR 1800 114TH AVENUE SE BELLEVUE WA 98004 COIN COLLE false 397786 15797 381989 397786 5523605 -5125819 All States MAN/WOMAN OF TH 4219087 4209899 9188 7675 830 683 3252 STUDENT OF THE 3335276 3324868 10408 10302 106 3732 339 157393006 152592466 4800540 3364586 931964 162918 270606 916475 164947369 160127233 4820136 3382563 932794 163707 270606 923459 5673129 -852993 false false 77510 2200 false 77510 2200 2200 75310 OH FL true false false false 1.00000 GORDON MILLER JR 3 INTERNATIONAL DRIVE SUITE 200 RYE BROOK NY 10573 false SEE SCHEDULE G PART IV false SCHEDULE G, PART IV SCHEDULE G PART I, LINE 2B LLS USED RESOURCE ONE, THOMPSON, HABIB & DENISON, AND MAIL AMERICA COMMUNICATIONS FOR ITS NATIONAL COMMUNITY CAMPAIGN AND DIRECT MAIL PROGRAMS. LLS USED COINSTAR FOR ITS COIN COLLECTION. SCHEDULE G PART II - LINE 2 CONTRIBUTIONS REPRESENT THE CASH DONATIONS IN EXCESS OF FAIR MARKET VALUE BENEFITS PROVIDED TO THE DONOR. SCHEDULE G PART III - LINE 9 - STATES WITH GAMING OPERATIONS UTAH, OHIO SCHEDULE G PART III - LINE 16 THE LEUKEMIA & LYMPHOMA SOCIETY DOES NOT HAVE AN OVERALL MANAGER FOR GAMING ACTIVITIES. EACH GAMING EVENT IS MANAGED LOCALLY BY THE SPECIFIC REGIONAL STAFF. true ALBERT EINSTEIN COLLEGE OF MEDICINE RESEARCH FINANCE 1300 MORRIS PARK AVE BELFER 1108 BRONX NY 10461 472209056 3 602666 ACCRUAL RESEARCH GRANT ATRIUM HEALTH FOUNDATION 208 EAST BOULEVARD ATTN ELECTA MCPHERSON CHARLOTTE NC 28203 566060481 3 110000 ACCRUAL RESEARCH GRANT BAYLOR COLLEGE OF MEDICINE BAYLOR COLLEGE OF MEDICINE P O BOX 301207 DALLAS TX 753031207 741613878 3 1275623 ACCRUAL RESEARCH GRANT BE THE MATCH FOUNDATION 500 N 5TH STREET MINNEAPOLIS MN 55401 411704340 3 200000 ACCRUAL RESEARCH GRANT BECKMAN RESEARCH INSTITUTE OF THE C 1500 EAST DUARTE ROAD ATTN VALERIE BINGHAM DUARTE CA 91010 953432210 3 1331722 ACCRUAL RESEARCH GRANT BOARD OF TRUSTEES OF THE LELAND STA STANFORD UNIVERSITY LOCKBOX PO BOX 44253 SAN FRANCISCO CA 941444253 941156365 3 1852192 ACCRUAL RESEARCH GRANT BOSTON CHILDREN'S HOSPITAL ATTN RESEARCH FINANCE PO BOX 414413 BOSTON MA 022414413 042774441 3 11299 ACCRUAL RESEARCH GRANT BOSTON UNIVERSITY RESEARCH ACCOUNTI PO BOX 28763 NEW YORK NY 100878763 042103547 3 139381 ACCRUAL RESEARCH GRANT BRIGHAM AND WOMENS HOSPITAL RESEARCH PO BOX 3149 BOSTON MA 022413149 042312909 3 104500 ACCRUAL RESEARCH GRANT BROAD INSTITUTE INC 7 CAMBRIDGE CENTER CAMBRIDGE MA 02142 263428781 3 15000 ACCRUAL RESEARCH GRANT CINCINNATI CHILDREN'S HOSPITAL MEDI 3333 BURNET AVENUE ML 4900 CINCINATTI OH 45229 310833936 3 253350 ACCRUAL RESEARCH GRANT CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND OH 44195 340714585 3 190000 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE RESEARCH ACCOUNTING MAIL STOP BP43 450 BROOKLINE AVENUE BOSTON MA 02215 042263040 3 3256293 ACCRUAL RESEARCH GRANT EMORY UNIVERSITY EMORY UNIVERSITY PO BOX 935084 ATLANTA GA 311935084 582137993 3 550000 ACCRUAL RESEARCH GRANT FRED HUTCHINSON CANCER RESEARCH CEN 1100 FAIRVIEW AVENUE NORTH J6-300 SEATTLE WA 981091024 237156071 3 2021795 ACCRUAL RESEARCH GRANT H LEE MOFFITT CANCER CENTER & RESE PO BOX 742801 ATLANTA GA 303742801 593238634 3 61919 ACCRUAL RESEARCH GRANT HACKENSACK MERIDIAN HEALTH 40 PROSPECT AVENUE ATTN DAVID CANDELMO OFFICE OF RE HACKENSACK NJ 07601 221487576 3 104194 ACCRUAL RESEARCH GRANT HARVARD MEDICAL SCHOOL PO BOX 415649 BOSTON MA 022415649 042103580 3 56833 ACCRUAL RESEARCH GRANT ICAHN SCHOOL OF MEDICINE AT MOUNT S ATTN RAJ APPAVU ONE GUSTAVE L LEVY PLACE BOX 350 NEW YORK NY 10029 136171197 3 120000 ACCRUAL RESEARCH GRANT INDIANA UNIVERSITY OFFICE OF RESEARCH ADMINISTRATION PO BOX 78000 DETROIT MI 482780867 356018940 3 347105 ACCRUAL RESEARCH GRANT INTERNATIONAL WALDENSTROM'S MACROGL 6144 CLARK CENTER AVE SARASOTA FL 34238 541784426 3 50000 ACCRUAL RESEARCH GRANT JOAN & SANFORD I WEILL MEDICAL COL 575 LEXINGTON AVE 9TH FL ATTN MELISSA PARAY NEW YORK NY 10022 131623978 3 645500 ACCRUAL RESEARCH GRANT MASSACHUSETTS GENERAL HOSPITAL MGH RESEARCH FINANCE PO BOX 414876 BOSTON MA 022414876 041564655 3 1118749 ACCRUAL RESEARCH GRANT MASSACHUSETTS INSTITUTE OF TECHNOLO 77 MASSACHUSETTS AVE NE18-901 CAMBRIDGE MA 02139 042103594 3 57000 ACCRUAL RESEARCH GRANT MAYO CLINIC ROCHESTER MAYO CLINIC RESEARCH PO BOX 860334 MINNEAPOLIS MN 554860334 416011702 3 260000 ACCRUAL RESEARCH GRANT MYELOPROLIFERATIVE NEOPLASMS RESEAR 180 N MICHIGAN AVENUE SUITE 1870 CHICAGO IL 60601 364330967 3 50000 ACCRUAL RESEARCH GRANT NEW YORK UNIVERSITY SCHOOL OF MEDIC SPONSORED PROGRAMS PO BOX 415026 BOSTON MA 022414150 135562308 3 858243 ACCRUAL RESEARCH GRANT NORTHWESTERN UNIVERSITY ACCOUNTING SERVICES FOR RESEARCH 633 CLARK - ROOM G547 EVANSTON IL 60208 362167817 3 414500 ACCRUAL RESEARCH GRANT OSU FOUNDATION 1960 KENNY ROAD 4TH FLOOR COLUMBUS OH 432101016 316025986 3 612312 ACCRUAL RESEARCH GRANT PERELMAN SCHOOL OF MEDICINE AT THE OFFICE OF RESEARCH SERVICES 3451 WALNUT STREET FRANKLIN BLDG P- PHILADELPHIA PA 191046205 231352685 3 121898 ACCRUAL RESEARCH GRANT REGENTS OF THE UNIVERSITY OF MICHIG BOX 223131 PITTSBURGH PA 152512131 386006309 3 582818 ACCRUAL RESEARCH GRANT ROCKEFELLER UNIVERSITY 1230 YORK AVENUE BOX 82 NEW YORK NY 10021 131624158 3 190000 ACCRUAL RESEARCH GRANT SEATTLE CHILDREN'S HOSPITAL 4800 SAND POINT WAY NE SEATTLE WA 98105 911156519 3 125000 ACCRUAL RESEARCH GRANT SLOAN KETTERING INSTITUTE FOR CANCE SLOAN KETTERING INSTITUTE FOR CANCE MSKC FINANCE GENERAL POST OFFICE PO NEW YORK NY 10087 131924236 3 484600 ACCRUAL RESEARCH GRANT ST JUDE CHILDREN'S RESEARCH HOSPIT PO BOX 1000 DEPT 949 MEMPHIS TN 381480949 620646012 3 489500 ACCRUAL RESEARCH GRANT TEMPLE UNIVERSITY RESEARCH ACCOUNTING SERVICES PO BOX 824242 PHILADELPHIA PA 191824242 231365971 3 210000 ACCRUAL RESEARCH GRANT THE CHILDREN'S HOSPITAL OF PHILADEL LOCKBOX 1457 PO BOX 8500 PHILADELPHIA PA 191781457 231352166 3 8325 ACCRUAL RESEARCH GRANT THE JACKSON LABORATORY 600 MAIN STREET BAR HARBOR ME 046091523 010211513 3 90000 ACCRUAL RESEARCH GRANT THE JOHNS HOPKINS UNIVERSITY SCHOOL JOHNS HOPKINS UNIVERSITY CENTRAL LO 12529 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 520595110 3 290000 ACCRUAL RESEARCH GRANT THE OHIO STATE UNIVERSITY 1960 KENNY ROAD 4TH FLOOR ATTN RICHARD BRADBURY COLUMBUS OH 432101016 316025986 3 162517 ACCRUAL RESEARCH GRANT THE REGENTS OF THE UNIVERSITY OF CA 9500 GILMAN DRIVE MC 0009 LA JOLLA CA 920930009 956006144 3 500000 ACCRUAL RESEARCH GRANT THE REGENTS OF THE UNIVERSITY OF CA UCSF MAIN DEPOSITORY PO BOX 748872 LOS ANGELES CA 900744872 946036493 3 363479 ACCRUAL RESEARCH GRANT THE TRUSTEES OF COLUMBIA UNIVERSITY SPONSORED PROJECTS FINANCE PO BOX 29789 NEW YORK NY 100879789 135598093 3 10000 ACCRUAL RESEARCH GRANT THE TRUSTEES OF COLUMBIA UNIVERSITY SPONSORED PROJECTS FINANCE PO BOX 29789 NEW YORK NY 100879789 135598093 3 172689 ACCRUAL RESEARCH GRANT THE TRUSTEES OF THE UNIVERSITY OF P OFFICE OF RESEARCH SERVICES 3451 WALNUT STREET FRANKLIN BLDG P PHILADELPHIA PA 191046205 231352685 3 1424086 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF ALABAMA AT BIRMIN 1530 3RD AVENUE SOUTH SUITE 1170 BIRMINGHAM AL 352940111 636005396 3 68350 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF CHICAGO 5841 S MARYLAND AVE MC6092 CHICAGO IL 60637 362177139 3 100000 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF NORTH CAROLINA AT OFFICE OF SPONSORED RESEARCH IN CA PO BOX 402420 ATLANTA GA 303842420 566001393 3 304435 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF TEXAS MD ANDERSON ATTN GRANTS AND CONTRACTS PO BOX 4266 HOUSTON TX 772104266 746001118 3 1631191 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF TEXAS SOUTHWESTER PO BOX 841753 DALLAS TX 752841753 756002868 3 304500 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF UTAH 201 S PRESIDENTS CIRCLE RM 145 ACCOUNTS PAYABLE SALT LAKE CITY UT 841129003 876000525 3 104500 ACCRUAL RESEARCH GRANT TUFTS MEDICAL CENTER 800 WASHINGTON STREET 453 BOSTON MA 02111 042103634 3 375680 ACCRUAL RESEARCH GRANT UNIVERSITY OF CALIFORNIA IRVINE OFFICE OF RESEARCH ADMINISTRATION 300 UNIVERSITY TOWER UNIVERSITY OF IRVINE CA 926977600 952540117 3 190000 ACCRUAL RESEARCH GRANT UNIVERSITY OF CHICAGO 6054 SOUTH DREXEL AVE SUITE 300 CHICAGO IL 60637 362177139 3 287302 ACCRUAL RESEARCH GRANT UNIVERSITY OF COLORADO DENVER ANSC ANSCHUTZ MEDICAL CAMPUS BLDG 500 PO BOX 6508 AURORA CO 80045 846000555 3 678754 ACCRUAL RESEARCH GRANT UNIVERSITY OF COLORADO-DENVER 12700 E 19TH AVENUE AURORA CO 80045 846000555 3 200000 ACCRUAL RESEARCH GRANT UNIVERSITY OF FLORIDA 33 TIGERT HALL P O BOX 113001 GAINESVILLE FL 326113001 596002052 3 1743668 ACCRUAL RESEARCH GRANT UNIVERSITY OF KENTUCKY 500 SOUTH LIMESTONE 109 KINKEAD HALL LEXINGTON KY 405060001 616033693 3 56997 ACCRUAL RESEARCH GRANT UNIVERSITY OF MARYLAND BALTIMORE PO BOX 41428 BALTIMORE MD 212036428 526002033 3 50000 ACCRUAL RESEARCH GRANT UNIVERSITY OF MIAMI OFFICE OF RESEARCH ADMINISTRATION PO BOX 405803 ATLANTA GA 303845803 590624458 3 1161500 ACCRUAL RESEARCH GRANT UNIVERSITY OF NOTRE DAME 511 MAIN BUILDING NOTRE DAME IN 46556 350868188 3 190000 ACCRUAL RESEARCH GRANT UNIVERSITY OF SOUTHERN CALIFORNIA SPONSORED PROJECTS ACCOUNTING FILE NO 52095 LOS ANGELES CA 90089 951642394 3 55000 ACCRUAL RESEARCH GRANT UNIVERSITY OF VIRGINIA ATTN OFFICE OF SPONSORED PROGRAMS PO BOX 400195 CHARLOTTESVILLE VA 229044195 237173411 3 104194 ACCRUAL RESEARCH GRANT VAN ANDEL RESEARCH INSTITUTE 333 BOSTWICK AVE NE GRAND RAPIDS MI 49503 522000820 3 5500 ACCRUAL RESEARCH GRANT VANDERBILT UNIVERSITY MEDICAL CENTE DEPT OF FINANCE ATTN STEVE TODD DEPT 1236 PO BOX 121236 DALLAS TX 75312 620476822 3 243750 ACCRUAL RESEARCH GRANT WASHINGTON UNIVERSITY IN ST LOUIS CAMPUS BOX 1034 700 ROSEDALE AVENUE ST LOUIS MO 63130 430653611 3 220000 ACCRUAL RESEARCH GRANT WASHINGTON UNIVERSITY SCHOOL OF MED SPONSORED PROJECTS ACCOUNTING 700 ROSEDALE AVENUE CAMPUS BOX 1034 ST LOUIS MO 631121408 430653611 3 455000 ACCRUAL RESEARCH GRANT WESTERN INSTITUTE FOR VETERANS RESE PO BOX 58719 SALT LAKE CITY UT 84158 870470748 3 70882 ACCRUAL RESEARCH GRANT YALE UNIVERSITY OFFICE OF SPONSORED PROJECTS PO BOX 1873 NEW HAVEN CT 065201873 060646973 3 312500 ACCRUAL RESEARCH GRANT CONSTELLATION 215 FIRST STREET SUITE 200 CAMBRIDGE MA 02142 270031381 50000 FMV THERAPY ACCELERATION ABINTUS BIO INC 10355 SCIENCE CENTER DR 250 SAN DIEGO CA 92121 844349617 250000 FMV THERAPY ACCELERATION JOHNS HOPKINS UNIV 733 N BROADWAY BALTIMORE MD 21231 520595110 20000 FMV THERAPY ACCELERATION 75 COPAY ASSISTANCE CLL 3388 13280647 COPAY ASSISTANCE LYMPHOMA 3480 10533758 COPAY ASSISTANCE MDS 2987 9998616 COPAY ASSISTANCE MYELOMA 11872 61505457 COPAY ASSISTANCE MANTEL 894 2975201 COPAY ASSISTANCE WALDENST 567 2168330 COPAY ASSISTANCE ALL 64 238812 COPAY ASSISTANCE AML 3288 10693411 COPAY ASSISTANCE CML 152 237174 PATIENT TRAVEL ASSISTANC 4944 2903009 PATIENT AID 9863 4091519 SCHEDULE I, PAGE 1, PART I, LINE 2 FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. PATIENT FINANCIAL AID: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR MANY EXPENSES RELATED TO THEIR TREATMENT. SOMETIMES PATIENTS HAVE TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE TREATMENT EXPENSES. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS HAS ESTABLISHED A PATIENT FINANCIAL AID PROGRAM THAT PROVIDES APPLICANTS, WHO RESIDE IN THE US AND HAVE A BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. CO-PAY ASSISTANCE: PATIENT APPLICATIONS ARE PROCESSED ON A FIRST COME, FIRST SERVED BASIS. ELIGIBLE PATIENTS MUST RESIDE IN THE UNITED STATES OR PUERTO RICO, HAVE A PROGRAM COVERED BLOOD CANCER DIAGNOSIS CONFIRMED BY A PHYSICIAN, MAINTAIN MEDICAL/PRESCRIPTION INSURANCE AND HAVE HOUSEHOLD INCOME AT OR BELOW 500% OF THE US FEDERAL POVERTY LEVEL AS ADJUSTED BY HOUSEHOLD SIZE AND COST OF LIVING INDEX. PATIENTS MUST PROVIDE PROOF OF INSURANCE AND INCOME. QUALIFYING PATIENTS ARE APPROVED FOR A TWELVE MONTH COVERAGE PERIOD. PATIENT TRAVEL ASSISTANCE: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR TRANSPORTATION TO GET TO THEIR PROVIDERS, E.G. DOCTORS, HOSPITALS, TRANSPLANT CENTERS, AND RESEARCH OR CLINICAL TRIAL CENTERS. SOMETIMES PATIENTS HAVE TO TRAVEL OUT-OF-STATE TO GET THEIR PRESCRIBED AND RECOMMENDED TREATMENTS, OFTENTIMES RESULTING IN PATIENTS HAVING TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS ESTABLISHED THE TRAVEL ASSISTANCE PROGRAM WHICH PROVIDES APPLICANTS, WHO ARE US CITIZENS OR PERMANENT RESIDENTS, HAVE AN ANNUAL INCOME AT OR BELOW 500% OF THE FEDERAL POVERTY LEVEL (FPL) AND HAVE A CONFIRMED BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. X X X X X true false false false false false false true false LOUIS J DEGENNARO PHD PRESIDENT & CEO 599504 330000 21012 14537 26721 991774 GWEN NICHOLS MD EVP CHIEF MED OFFICE 380665 25565 758 26439 433427 TROY DUNMIRE - START 1132020 EVP CHIEF OPER OFFIC 407443 1111 20814 429368 VANESSA WHITE SVP CHIEF ADV OFF 354266 1201 4703 21514 381684 LEE M GREENBERGER SVP CHIEF SCIEN OFFI 306565 18978 6118 36248 367909 KATHY GRIESENBECK - END 7312020 EVP CHIEF REL OFFICE 214806 132900 6365 11492 365563 COKER POWELL EVP PROD CAMP DEV 300001 20244 4342 40118 364705 GORDON MILLER JR EVP CHIEF FIN OFFICE 319573 1655 6469 29843 357540 MARGO LUCERO - END 7312020 EVP CORP PARTNERSHIP 199983 136383 19808 356174 ROSEMARIE ALOFFREDO - END 3312019 CHIEF FIN OFFICER 177503 177503 SCHEDULE J, PAGE 1, PART I, LINE 4 KATHY GRIESENBECK - END 7/31/2020 127,308 0 0 MARGO LUCERO - END 7/31/2020 135,416 0 0 ROSEMARIE A.LOFFREDO - END 3/31/2019 177,503 0 0 SCHEDULE J, PAGE 1, PART I, LINE 7 BONUS WAS A RETENTION BONUS PAID BASED ON MILESTONE ACHIEVEMENT AS PER CONTRACT. X 217 1575597 FAIR MARKET VALUE X 2 X PRINTED ITEMS 8 X VARIOUS OTHER 35 208680 false true false SCHEDULE M, PAGE 2, PART II PART I, COLUMN (B) LLS IS REPORTING THE NUMBER OF CONTRIBUTIONS FOR EACH OF THE ITEMS IN PART I, NOT THE NUMBER OF INDIVIDUAL ITEMS. PART I, LINE 33 - EXPLANATION FOR NOT REPORTING REVENUE LLS ONLY RECORDS DONATED SECURITIES AS REVENUE. ALL OTHER ITEMS FOR WHICH COLUMN A IS CHECKED ARE NOT RECORDED AS REVENUE OR EXPENSE BECAUSE THEY WOULD NOT HAVE BEEN PURCHASED HAD THEY NOT BEEN DONATED, AND ARE IMMATERIAL IN AMOUNT RELATIVE TO THE STATEMENTS OF LLS. FORM 990, PAGE 2, PART III, LINE 4A A) RESEARCH PROGRAMS: AT LLS, WE ARE PUSHING BOUNDARIES TOWARD POWERFUL NEW THERAPIES. WE PROPEL GROUNDBREAKING CANCER TREATMENTS THROUGH ALL PHASES OF THE DRUG APPROVAL PROCESS AND ARE PROUD THAT OUR SUPPORT HAS BEEN KEY TO ADVANCING 75% OF THE ALMOST 100 BLOOD CANCER TREATMENT APPROVALS OVER THE LAST FIVE YEARS. AS WE CONTINUED TO SUPPORT THE SEARCH FOR LIFESAVING AND LESS TOXIC TREATMENTS IN 2021, WE INVESTED IN EXCITING RESEARCH FRONTIERS, INCLUDING PRECISION MEDICINE, IMMUNOTHERAPY, AND LINKS BETWEEN MUTATIONS AND BLOOD CANCER-ADVANCEMENTS THAT ARE CHANGING THE PARADIGM OF CANCER TREATMENT. IN THE PROCESS, WE PROPELLED SEVERAL NOVEL SCIENCE INITIATIVES TO NEW HEIGHTS-MANY OF WHICH HARDLY SEEMED POSSIBLE JUST A SHORT TIME AGO. WITH ADVISORY INPUT FROM RECOGNIZED BIOMEDICAL RESEARCH EXPERTS, LLS FUNDS EXEMPLARY PROJECTS ACROSS THE ENTIRE RESEARCH CONTINUUM RELEVANT TO IMPROVE OUTCOMES FOR BLOOD CANCER PATIENTS, FROM BASIC LABORATORY SCIENCE THROUGH CLINICAL TRIALS, AND FROM INVESTIGATOR-INITIATED RESEARCH TO PRIVATE-SECTOR DRUG DEVELOPMENT ALLIANCES. LLS IS DELIBERATE AND PURPOSEFUL IN FINDING AND SUPPORTING RESEARCH THAT IS MOST LIKELY TO HELP PATIENTS AS SOON AS POSSIBLE. TO DATE, LLS HAS INVESTED OVER 1.5 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. IN FISCAL YEAR 2021, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 6 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 33.9 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. IMPACT RESEARCH GRANTS TO ADDRESS UNEQUAL REPRESENTATION OF UNDERSERVED POPULATIONS IN CLINICAL TRIALS, IN MAY WE INTRODUCED IMPACT (INFLUENTIAL MEDICINE PROVIDING ACCESS TO CLINICAL TRIALS) RESEARCH GRANTS. AN INITIAL FIVE-YEAR INVESTMENT OF 3.75 MILLION WAS ALLOCATED TO MAYO CLINIC, VANDERBILT UNIVERSITY MEDICAL CENTER, AND WEILL CORNELL MEDICINE IN NEW YORK CITY. THE IMPACT GRANTS WILL HELP THESE MAJOR CANCER CENTERS EXPAND CLINICAL TRIAL ACCESS TO LOCAL COMMUNITY-BASED HOSPITALS AND CLINICS WITH SUBSTANTIAL UNDERSERVED POPULATIONS. THE GOAL IS TO INCREASE TRIAL ENROLLMENT AMONG TRADITIONALLY UNDERSERVED POPULATIONS, INCLUDING RACIAL AND ETHNIC MINORITIES, RURAL RESIDENTS, AND INDIVIDUALS WITH LOW INCOME, TO AT LEAST 20%, THEREBY EXPANDING ACCESS TO STATE-OF-THE-ART THERAPIES TO A BROADER SWATH OF NEWLY DIAGNOSED BLOOD CANCER PATIENTS. THERAPY ACCELERATION PROGRAM (TAP) SINCE 2007, OUR INNOVATIVE VENTURE PHILANTHROPY INITIATIVE, THE LLS THERAPY ACCELERATION PROGRAM (TAP), HAS PARTNERED WITH BIOTECHNOLOGY COMPANIES AND ACADEMIC RESEARCHERS TO EXTEND THE THERAPEUTIC LANDSCAPE IN LEUKEMIA, LYMPHOMA, AND MULTIPLE MYELOMA. IN 2021, WE MADE SIX NEW INVESTMENTS IN COMPANIES DEVELOPING NEW IMMUNOTHERAPIES INCLUDING "OFF THE SHELF" CAR T-CELL THERAPY, "IN VIVO" THERAPY THAT GENERATES CANCER-FIGHTING CAR CELLS INSIDE THE BODY, TWO FIRST-IN-CLASS ANTIBODIES TARGETING NOVEL CHECKPOINTS, TO RELEASE THE BRAKES AND ACTIVATE IMMUNE CELLS SO THEY CAN FIGHT CANCER, AND CAR- MACROPHAGE (CAR-M) THERAPY TO TREAT CANCERS WHERE CHECKPOINT INHIBITORS TEND TO BE LESS EFFECTIVE. NATIONAL PATIENT REGISTRY COVID INFORMATION THE ONGOING COVID-19 PANDEMIC ENGENDERED A HOST OF FEARS AND QUESTIONS FOR THE BLOOD CANCER COMMUNITY. WHEN PATIENT CONCERNS AROSE ABOUT WHETHER THE NEW VACCINES WOULD PROTECT THEM, LLS STEPPED IN TO FIND ANSWERS. IN FEBRUARY 2021, LLS ACTIVATED THE LLS NATIONAL PATIENT REGISTRY, A PROJECT SUPPORTED BY ETHEL AND BERNARD GARIL IN MEMORY OF THEIR SON, MICHAEL, WHO SUCCUMBED TO ACUTE LYMPHOBLASTIC LEUKEMIA. MORE THAN 10,000 BLOOD CANCER PATIENTS ANSWERED THE CALL TO JOIN THE REGISTRY AS "CITIZEN SCIENTISTS." THIS ALLOWED US TO GENERATE THE LARGEST DATA SET REPORTED TO DATE ON VACCINE SAFETY AND EFFICACY(INCLUDING BOOSTERS) ACROSS ALL MAJOR BLOOD CANCER AND TREATMENT TYPES. THIS INFORMATION HAS HELPED PATIENTS, HEALTHCARE PROVIDERS, AND PUBLIC HEALTH OFFICIALS MAKE MORE INFORMED CHOICES ABOUT COVID-19 PREVENTION. CLINICAL TRIALS BEAT AML MASTER TRIAL BEGINNING NOVEMBER 2016, LLS LAUNCHED THE BEAT AML MASTER TRIAL, A COLLABORATIVE CLINICAL TRIAL TESTING SEVERAL NOVEL TARGETED THERAPIES FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) DESIGNED TO FACILITATE FDA APPROVAL OF NEW DRUGS AND CHANGE THE TREATMENT PARADIGM FOR PATIENTS DIAGNOSED WITH AML BY DEVELOPING MORE INDIVIDUALIZED, EFFECTIVE TREATMENT APPROACHES. THE MASTER TRIAL INVOLVES COLLABORATIONS WITH MULTIPLE MEDICAL INSTITUTIONS, DRUG COMPANIES, A GENOMIC PROVIDER, A CLINICAL RESEARCH ORGANIZATION, AND THE FDA, ALL OF WHOM HAVE COMMITTED TO WORKING COLLABORATIVELY. IN FISCAL YEAR 2021, UP TO 35 PATIENTS PARTICIPATED IN CLINICAL TRIALS UNDER THE BEAT AML MASTER TRIAL. FORM 990, PAGE 2, PART III, LINE 4B B) PATIENT & COMMUNITY SERVICES: AN ESTIMATED 1.3 MILLION PEOPLE ACROSS THE UNITED STATES (US) ARE CURRENTLY LIVING WITH OR ARE IN REMISSION FROM LEUKEMIA, LYMPHOMA AND MYELOMA. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) OFFERS AN ARRAY OF FREE, COMPREHENSIVE RESOURCES TO BLOOD CANCER PATIENTS, CAREGIVERS, FAMILIES AND FRIENDS OF PATIENTS, ADVOCATES, HEALTHCARE PROFESSIONALS AND THE PUBLIC. LLS IS COMMITTED TO PROVIDING THE MOST ACCURATE AND UP-TO-DATE BLOOD CANCER INFORMATION. PROFESSIONAL VOLUNTEER CLINICAL ADVISORS WORK WITH LLS STAFF TO REVIEW ALL OF THE INFORMATION LLS PROVIDES THROUGH HEALTHCARE PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE LLS WEBSITE. SUPPORT SERVICES ARE PROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE-TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. FINANCIAL ASSISTANCE OUR FINANCIAL ASSISTANCE PROGRAMS AIM TO LESSEN THE ECONOMIC TOLL ON PATIENTS AND FAMILIES TO HELP PATIENTS AFFORD LIFE-SAVING TREATMENTS. TO COUNTER CONTINUALLY RISING DRUG PRICES AND THE ONGOING FINANCIAL IMPACT OF COVID-19, WE PROVIDED MORE THAN 45,000 PATIENTS WITH OVER 241M IN TOTAL GRANTS, A 70% INCREASE OVER LAST YEAR. THE LION'S SHARE-OVER 234 MILLION- SUPPORTED PATIENTS' INSURANCE PREMIUMS AND TREATMENT-RELATED CO-PAY AND CO-INSURANCE OUT OF POCKET COSTS THROUGH OUR CO-PAY ASSISTANCE PROGRAM. IN KEEPING WITH OUR COMMITMENT TO DIVERSITY, EQUITY, AND INCLUSION, LLS RECOGNIZES THAT NEED EXISTS THROUGHOUT ALL GEOGRAPHIC REGIONS AND WITHIN ALL PATIENT POPULATIONS, INCLUDING THOSE TRADITIONALLY UNDERREPRESENTED. IN 2021, FINANCIAL ASSISTANCE WAS PROVIDED TO PATIENTS WHO RESIDED IN 55% OF ALL U.S. COUNTIES AND 51% OF THE COUNTIES ACROSS THE U.S. WITH THE HIGHEST POVERTY RATES. CO-PAY ASSISTANCE PROGRAM THE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO- PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2021, CO-PAY ASSISTANCE WAS PROVIDED TO OVER 22,000 PATIENTS. SUSAN LANG PRE CAR T-CELL THERAPY TRAVEL ASSISTANCE PROGRAM LLS PROVIDED OVER 200 GRANTS, EACH 2,500, FOR TREATMENT-RELATED TRANSPORTATION AND LODGING COSTS FOR PATIENTS WHO ARE BEING EVALUATED TO RECEIVE CAR T-CELL THERAPY AS EITHER STANDARD TREATMENT OR A CLINICAL TRIAL. SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM LLS AWARDED A 500 GRANT TO OVER 4,750 PATIENTS FOR TREATMENT-RELATED TRANSPORTATION AND LODGING COSTS. URGENT NEED PROGRAM IN PARTNERSHIP WITH MOPPIE'S LOVE AND CHARLIE'S FUND, LLS PROVIDED A 500 GRANT TO NEARLY 9,000 PATIENTS AND FAMILIES IN ACUTE FINANCIAL NEED FOR NON-MEDICAL LIVING EXPENSES-INCLUDING RENT, UTILITIES AND FOOD. PATIENT AID PROGRAM LLS PROVIDED A ONE-TIME STIPEND OF 100 TO OVER 3,700 PATIENTS TO HELP OFFSET NON-MEDICAL EXPENSES. SCHOLARSHIP FOR BLOOD CANCER SURVIVORS NEW IN 2021 WAS THE INTRODUCTION OF LLS'S SCHOLARSHIP FOR BLOOD CANCER SURVIVORS PROVIDING UP TO 7,500 IN TUITION SUPPORT FOR PATIENTS DIAGNOSED BEFORE AGE 25, ARE U.S. CITIZENS OR PERMANENT RESIDENTS PURSUING VIRTUAL OR IN-PERSON, VOCATIONAL, 2 YEAR OR 4 YEAR POST-SECONDARY EDUCATION. FORM 990, PAGE 2, PART III, LINE 4C C) PUBLIC HEALTH EDUCATION: LLS BELIEVES KNOWLEDGE IS POWER. AS ALWAYS, LLS HAS OFFERED THEIR INFORMATIONAL PROGRAMS IN VIRTUAL FORMATS, CONTINUING TO PROVIDE VITALLY NEEDED EDUCATION AND EMOTIONAL SUPPORT FOR THOSE IMPACTED BY BLOOD CANCER. ONGOING PANDEMIC CONCERNS TRAINED ONCOLOGY INFORMATION SPECIALISTS IN OUR INFORMATION RESOURCE CENTER (IRC) WERE AVAILABLE TO ANSWER PANDEMIC-RELATED AND OTHER QUESTIONS. OVER 26,000 INTERACTIONS BETWEEN THE IRC AND PATIENTS AND CAREGIVERS TOOK PLACE, WITH AVERAGE CALL LENGTHS UP 30% OVER 2020. FACILITATING CLINICAL TRIAL ACCESS THE LLS CLINICAL TRIAL SUPPORT CENTER (CTSC) GREW THROUGHOUT THE YEAR AS WE INCREASED OUR BI-LINGUAL AND PEDIATRIC EXPERTISE AMONG THE CTSC NURSE NAVIGATORS, AND CONTINUED TO EXPAND THE POSSIBILITY OF POSITIVE OUTCOMES FOR PATIENTS BY MATCHING THEM TO SUITABLE CLINICAL TRIALS. OUR NURSE NAVIGATORS ASSISTED 1,019 PATIENTS (UP 31% FROM 2020). OF THE 759 NEW PATIENTS ASSISTED (UP 31% FROM LAST YEAR), 21% ENTERED A TRIAL. WE WERE HONORED THAT A CTSC TEAM-AUTHORED ARTICLE, OVERCOMING BARRIERS TO CLINICAL TRIAL PARTICIPATION: OUTCOMES OF A NATIONAL CLINICAL TRIAL MATCHING AND NAVIGATION SERVICE FOR PATIENTS WITH A BLOOD CANCER, WAS PUBLISHED IN THE "JOURNAL OF CLINICAL ONCOLOGY, ONCOLOGY PRACTICE" IN MAY. OUTREACH TO UNDERSERVED GROUPS WE AUGMENTED EFFORTS TO EXPAND ACCESS TO LLS SERVICES AND RESOURCES BY BOLSTERING RELATIONS WITH COMMUNITY GROUPS AND LEADERS, NOTABLY IN THE AFRICAN AMERICAN AND LATINO COMMUNITIES, AND INCREASED OUR NUMBER OF BILINGUAL VOLUNTEERS. WE ALSO INCREASED ACCESSIBILITY OF OUR EDUCATION PROGRAMS TO RURAL PATIENTS AND FAMILIES VIA OUR VIRTUAL OFFERINGS. MOREOVER, WE EXPANDED PARTNERSHIPS WITH AFFINITY GROUPS INCLUDING: THE COALITION OF 100 BLACK WOMEN, THE MEXICAN CONSULATE'S VENTANILLA DE SALUD PROGRAM,AND PROMOTORES (VISION Y COMPROMISO). THE LLS MYELOMA LINK PROGRAM, LAUNCHED IN 2017, CONTINUED TO GAIN TRACTION. WE IMPROVED UNDERSTANDING OF TREATMENT OPTIONS BY PROVIDING IMPORTANT INFORMATION TO AFRICAN AMERICANS, WHO ARE TWICE AS LIKELY TO BE DIAGNOSED WITH MULTIPLE MYELOMA AS CAUCASIAN AMERICANS. IN 2021, LLS REACHED APPROXIMATELY 10,448 PEOPLE THROUGH MORE THAN 72 MYELOMA LINK EDUCATION AND OUTREACH ACTIVITIES IN 13 CITIES. EDUCATION AND PATIENT CONNECTIONS OUR VIRTUAL EDUCATION PROGRAMS PROVIDED BOTH PATIENTS AND FAMILIES, AS WELL AS HEALTH CARE PROFESSIONALS, ACCESS TO CONTENT INCLUDING BLOOD CANCER CONFERENCES, LOCAL EDUCATION PROGRAMS, NATIONAL WEBINARS, VIDEOS, LECTURES, AND PODCASTS. LLS'S HIGHLY VIEWED WEBSITE CONTINUES TO PROVIDE THE MOST UP TO DATE BLOOD CANCER INFORMATION INCLUDING ACCESS TO BLOGS, BOOKLETS, WORKBOOKS, FACT SHEETS AND MORE. IN ADDITION, NEARLY 1,000 CANCER PATIENTS WERE PROVIDED WITH PERSONALIZED NUTRITION CONSULTATIONS BY LLS'S REGISTERED DIETITIAN. OUR PATIENT & COMMUNITY OUTREACH TEAM CONTINUED TO BRING PATIENTS TOGETHER VIA ONLINE LOCAL SUPPORT GROUPS AND CHATS. THE PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM MATCHED NEARLY 1,800 PATIENTS (UP 5% FROM 2020) WITH TRAINED VOLUNTEERS FACING THE SAME DISEASE, HELPING TO AVERT PANDEMIC-RELATED ISOLATION. IN ADDITION, MEMBERSHIP IN LLS COMMUNITY-OUR ONLINE SOCIAL NETWORK-INCREASED 23% OVER 2020. FORM 990, PAGE 2, PART III, LINE 4D D) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. UPCOMING AND ARCHIVED CE/CME PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/CE. IN FY 2021: -LLS PROVIDED 14 CME/CE-GRANTING VIRTUAL EDUCATIONAL PROGRAMS, WITH 2,345 HEALTHCARE PROFESSIONALS IN ATTENDANCE. --THERE WERE 44,790 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS, 25,541 VIRTUAL LECTURE VIEWS AND 14,107 PODCAST DOWNLOADS. FORM 990, PART V, LINE 4B CANADA FORM 990, PAGE 6, PART VI, LINE 11B THE FORM 990 WAS PREPARED BY THE LLS FINANCE DEPARTMENT AND WAS REVIEWED BY THE CFO, VICE PRESIDENT, CONTROLLER, AND KPMG FOR COMMENT AND SUGGESTED REVISIONS. THE FORM 990 WAS THEN PROVIDED TO THE AUDIT COMMITTEE, WHICH IS A COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWED THE 990 AND PROVIDED INPUT PRIOR TO FILING. THE FINAL DRAFT FORM 990, AS WILL BE FILED WITH THE IRS, WAS PROVIDED TO THE ENTIRE BOARD OF DIRECTORS PRIOR TO FILING WITH THE IRS. FORM 990, PAGE 6, PART VI, LINE 12C ALL EMPLOYEES, VOLUNTEERS, CONSULTANTS, TEMPORARY EMPLOYEES, LOCAL BOARD MEMBERS, AND MEMBERS OF THE NATIONAL BOARD OF DIRECTORS ARE REQUIRED TO REVIEW THE CONFLICT OF INTEREST POLICY ON AN ANNUAL BASIS AND SUBMIT A SIGNED FORM ACKNOWLEDGING THAT THEY HAVE REVIEWED THE POLICY AND DISCLOSED ANY CONFLICTS OF INTEREST. ALL CONFLICT OF INTEREST DISCLOSURE FORMS ARE REVIEWED BY THE LEGAL DEPARTMENT AND, IF DEEMED NECESSARY, ESCALATED TO THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS FOR FURTHER REVIEW, EVALUATION, AND/OR MANAGEMENT OF ANY ACTUAL OR APPARENT CONFLICTS OF INTEREST. FORM 990, PAGE 6, PART VI, LINE 15A THE EXECUTIVE COMMITTEE COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS REVIEWS, MONITORS, AND APPROVES THE CHIEF EXECUTIVE OFFICER'S PERFORMANCE AND COMPENSATION. THEIR DECISION IS INCLUDED IN THE APPROPRIATE MINUTES OF THE MEETING IN WHICH APPROVAL WAS GIVEN. IN 2020, THE EXECUTIVE COMMITTEE, THROUGH AN INDEPENDENT THIRD PARTY, OBTAINED A MARKET STUDY COMPRISED OF SIMILAR NOT-FOR-PROFIT ORGANIZATIONS TO REVIEW THE COMPENSATION MARKET LEVELS AND SET THE CHIEF EXECUTIVE'S SALARY COMMENSURATELY. THE COMMITTEE MET, APPROVED AND DOCUMENTED THE PROCESS IN THE COMMITTEE MINUTES. FORM 990, PAGE 6, PART VI, LINE 15B IN 2020, THE EXECUTIVE COMMITTEE, THROUGH AN INDEPENDENT THIRD PARTY, OBTAINED A MARKET STUDY COMPRISED OF SIMILAR NOT-FOR-PROFIT ORGANIZATIONS TO REVIEW THE COMPENSATION MARKET LEVELS OF OTHER OFFICERS AND KEY EMPLOYEES AND TO APPROVE THE PRESIDENT AND CEO'S RECOMMENDATIONS ON THEIR COMPENSATION LEVELS. FORM 990, PAGE 6, PART VI, LINE 17 ILLINOIS, INDIANA, KANSAS, KENTUCKY, LOUISIANA, MASSACHUSETTS, MARYLAND, MAINE, MICHIGAN, MINNESOTA, MISSOURI, MISSISSIPPI, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEBRASKA, NEW YORK, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, PUERTO RICO, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, UTAH, VIRGINIA, WASHINGTON, WISCONSIN, WEST VIRGINIA FORM 990, PAGE 6, PART VI, LINE 19 THE LEUKEMIA & LYMPHOMA SOCIETY, INC. MAKES ITS ANNUAL FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE AT WWW.LLS.ORG. ITS GOVERNING DOCUMENTS ARE MADE AVAILABLE UPON REQUEST FOR PUBLIC INSPECTION. ANY IDENTIFIED CONFLICTS OF INTEREST ARE DISCLOSED IN THE 990. FORM 990, PART XI, LINE 9 MISC ROUNDING -2,054 BEAT AML LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY 12281252 4921911 LLS LLS PEDAL INITIATIVE LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY -1187768 LLS LLS TAP FORTY SEVEN LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY LLS LLS TAP MIRAGEN LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY LLS LLS TAP X4 LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY 1980000 LLS LLS TAP LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY 2869351 4588434 LLS LLS TAP CONSTELLATION LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY LLS LLS TAP AFFIRMED LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY LLS LLS TAP SUTRO LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY LLS LLS TAP JOHNS HOPKINS LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY LLS LLS TAP SELVITA LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY LLS LLS TAP VERASTEM LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY LLS LLS TAP KDAC LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY LLS THE LLS RESEARCH PROGRAMS INC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 133470494 PART VII DE 501C3 12A LLS INC true THE LLS RESEARCH FOUNDATION 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 133709252 PART VII DE 501C3 12A LLS INC true THE LLS OF CANADA 804 2 LANSING SQUARE TORONTO CA M2J4P8 PART VII CA NA false false false false false false false false false false false false false false false false false false false false SCHEDULE R THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA CARRIES OUT THE SAME PRIMARY ACTIVITIES AS THE LEUKEMIA & LYMPHOMA SOCIETY, INC., BUT IN CANADA. THE LEUKEMIA SOCIETY RESEARCH PROGRAMS, INC. AND THE LEUKEMIA RESEARCH FOUNDATION, INC. SUPPORT THE ACTIVITIES OF THE LEUKEMIA & LYMPHOMA SOCIETY, INC.